{
  "outcomes_metadata": {
    "timestamp": "2025-10-01T11:10:31.019120",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 41,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "overall survival (time from randomisation to death from any cause)",
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST v1.1)",
        "progression-free survival (blinded independent central review)",
        "progression-free survival (independent review panel, RECIST 1.1)",
        "event-free survival",
        "eventless survival",
        "prolonged survival",
        "quality-adjusted life years (QALYs)",
        "health-related quality of life (measured by time to death)"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (RECIST 1.1)",
        "objective response rate (independent review committee, RECIST 1.1)",
        "overall response rate",
        "response rates",
        "disease control rate",
        "disease control rate (proportion of patients with complete, partial, or stable disease for at least 5 weeks)",
        "duration of response (DoR)",
        "duration of response (RECIST 1.1)",
        "time to response (time from treatment initiation to first complete or partial response)",
        "treatment duration",
        "duration of treatment"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to next treatment (TTNT)",
        "time to next treatment"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (CTCAE v5.0)",
        "adverse events (CTCAE v4.03)",
        "adverse events",
        "side effects",
        "adverse drug reactions",
        "diarrhoea",
        "alanine aminotransferase increase",
        "aspartate aminotransferase increase",
        "neutropenia",
        "fatigue",
        "febrile neutropenia",
        "mortality-related toxicity",
        "serious side effects on the skin"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse events (Grade 3-4)",
        "serious undesirable effects"
      ],
      "discontinuations": [
        "dropout rate"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "BPI-SF",
        "FACT-G GP5",
        "PGI-C",
        "EQ-5D-5L",
        "visual analogue scale"
      ],
      "functional_status": [
        "Karnofsky performance status",
        "ECOG performance status",
        "physical functioning"
      ],
      "symptom_measures": [
        "symptomatology",
        "symptom control",
        "health status",
        "overall health status",
        "health-related quality of life",
        "preservation of quality of life",
        "quality of life"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness (cost per QALY)"
      ],
      "utilities": [
        "utility decrement per cycle of treatment"
      ],
      "resource_utilization": []
    },
    "other": {
      "exploratory_endpoints": [],
      "biomarkers": []
    }
  }
}